Literature DB >> 32164966

Isotretinoin.

Nasr Y Khalil1, Ibrahim A Darwish2, Abdulmohsen A Al-Qahtani1.   

Abstract

Isotretinoin is chemically named as: (2Z, 4E, 6E, 8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid. It is an orally active retinoic acid derivative for the treatment of severe refractory nodulocystic acne. It acts primarily by reducing sebaceous gland size and sebum production, and as a result alters skin surface lipid composition. Using isotretinoin for 1-2mg/kg/day for 3-4 months produces 60%-95% clearance of inflammatory lesions in patients with acne. Doses as low as 0.1mg/kg/day have also proven successful in the clearance of lesions. Encouraging results have also been seen in small numbers of patients with rosacea, Side effects affecting the mucocutaneous system and raised serum triglyceride levels occur in most patients receiving isotretinoin. Isotretinoin is strictly contraindicated in women of childbearing potential. This profile discusses and explains names of isotretinoin, its physical and chemical characteristics. It also includes methods of preparation, thermal and spectral behavior, methods of analysis, and pharmacology.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-acne; Isotretinoin; Methods of analytical; Pharmacology; Physical and chemical characteristics; Preparation

Year:  2019        PMID: 32164966     DOI: 10.1016/bs.podrm.2019.10.005

Source DB:  PubMed          Journal:  Profiles Drug Subst Excip Relat Methodol        ISSN: 1871-5125


  2 in total

1.  Efficacy and safety of low-level light therapy by delicate pulsed light combined with low-dose oral isotretinoin for the treatment of acne vulgaris: a randomized split-face study.

Authors:  Weihui Zeng; Zhao Wang; Youbao Li; Jun Xia; Yu Zhu; Shujuan He; Jing Liu
Journal:  Lasers Med Sci       Date:  2022-07-13       Impact factor: 2.555

2.  Successful treatment of ivermectin refractory demodicosis with isotretinoin and permethrin cream.

Authors:  Anon Paichitrojjana; Anand Paichitrojjana
Journal:  JAAD Case Rep       Date:  2022-07-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.